Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway.
Détails
ID Serval
serval:BIB_C908ED41AF0D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway.
Périodique
Oncogene
ISSN
0950-9232 (Print)
ISSN-L
0950-9232
Statut éditorial
Publié
Date de publication
06/01/2005
Peer-reviewed
Oui
Volume
24
Numéro
1
Pages
199-211
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
Alteration of methylation status has been recognized as a possible epigenetic mechanism of selection during tumorigenesis in pancreatic cancer. This type of cancer is characterized by poor prognosis partly due to resistance to conventional drug treatments. We have used microarray technology to investigate the changes in global gene expression observed after treatment of different pancreatic cancer cell lines with the methylase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR). We have observed that this agent is able to inhibit to various degrees the growth of three pancreatic cancer cell lines. In particular, this inhibition was associated with induction of interferon (IFN)-related genes, as observed in other tumour types. Thus, expression of STAT1 seems to play a key role in the cellular response to treatment with the cytosine analogue. Moreover, we found increased p21(WAF1) and gadd45A expression to be associated with the efficacy of the treatment; this induction may correlate with activation of the IFN signalling pathway. Expression of the p16(INK) protein was also linked to the ability of cells to respond to 5-aza-CdR. Finally, genome-wide demethylation induced sensitization that significantly increased response to further treatment with various chemotherapy agents.
Mots-clé
Antimetabolites, Antineoplastic/pharmacology, Antineoplastic Agents/pharmacology, Azacitidine/analogs & derivatives, Azacitidine/pharmacology, Cisplatin/pharmacology, DNA Methylation/drug effects, DNA Modification Methylases/antagonists & inhibitors, Decitabine, Deoxycytidine/analogs & derivatives, Deoxycytidine/pharmacology, Gene Expression Profiling, Gene Expression Regulation, Neoplastic/drug effects, Humans, Interferon-gamma/pharmacology, Interferons/metabolism, Pancreatic Neoplasms/drug therapy, Pancreatic Neoplasms/enzymology, Signal Transduction/drug effects, Gemcitabine
Pubmed
Web of science
Création de la notice
26/09/2023 8:53
Dernière modification de la notice
04/10/2023 13:28